A consortium of Canadian and American researchers report in Nature Genetics the results from a search of the entire human genome for genetic risk factors leading to the development of Crohn’s disease.
Childhood obesity may be associated with a condition known as otitis media with effusion, which consists of fluid build-up in the middle ear space without symptoms of acute ear infection, according to a report in the April issue of Archives of Otolaryngology — Head & Neck Surgery, one of the JAMA/Archives journals.
Individuals whose melanoma is diagnosed by a dermatologist may be more likely to have early-stage cancer and to survive five years than those with melanoma diagnosed by a nondermatologist, according to a report in the April issue of Archives of Dermatology, one of the JAMA/Archives journals.
Relying on one of the largest collections of liver tissue samples ever acquired by a single organization, Geisinger Health System researchers have embarked on a massive study of one of the fastest growing liver problems.
A vaccine for treating a recurrent cancer of the central nervous system that occurs primarily in the brain has shown promise in preliminary data from a clinical trial at the University of California, San Francisco.
A Rhode Island Hospital study presented today at the Society for Healthcare Epidemiology of America (SHEA) annual meeting found that patients in long-term elder care and HIV-infected outpatients appear to be high-risk groups for carriage of methicillin-resistant Staphylococcus aureus (MRSA), a common cause for health care associated infections.
Epidemiologists have unexpectedly found that African Americans had a higher rate of recurrence following prostate cancer surgery than did whites, regardless of whether or not patients received surgery at hospitals or by surgeons who performed a high number of such operations.
Five leading experts will be featured in a special half-day symposium on state-of-the-art obesity management in women at the 15th Annual Congress on Women?s Health, June 2-5, 2007, Hilton Head, SC at the Hilton Head Marriott Beach & Golf Resort.
Preliminary results from a large, randomized, placebo-controlled clinical trial for patients with primary gastrointestinal stromal tumor (GIST), a type of tumor usually found in the stomach or small intestine, showed that patients who received imatinib mesylate (Gleevec ?) after complete removal of their tumor were significantly less likely to have a recurrence of their cancer compared to those who did not receive imatinib.
Gleevec, a pill developed in conjunction with Oregon Health & Science University is again showing excellent results in preventing cancer recurrence in GIST patients after complete removal of their tumors.